---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-004406"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2022-02-09T23:59:59+00:00"
generated_at: "2026-06-27T09:37:03.370486+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics Q4 net loss $12.4M; clinical hold on VK0214; cash $202.1M

## Summary
- Net loss $12.4M ($0.16/share) for Q4 2021 vs $10.9M ($0.15) year ago; FY net loss $55.0M ($0.71) vs $39.5M ($0.54).
- Cash, equivalents, short-term investments $202.1M at Dec 31, 2021, down from $248.4M a year ago.
- FDA placed Phase 1b trial of VK0214 (X-ALD) on clinical hold; expects to submit requested preclinical data in Q2 2022.
- Phase 1 trial of dual GLP-1/GIP agonist VK2735 initiated; data expected in 2H22.
- Phase 2b VOYAGE trial of VK2809 for NASH continuing enrollment; initial data expected by end of 2022.

## SEC filing metadata
- accession: 0001564590-22-004406
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2022-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459022004406/0001564590-22-004406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459022004406/vktx-8k_20220209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-004406
- JSON: https://secwatch.observer/filing/0001564590-22-004406.json
- Plain text: https://secwatch.observer/filing/0001564590-22-004406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.